Dr. Kuykendall on the Approval of Fedratinib in Myelofibrosis

Video

In Partnership With:

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

Andrew T. Kuykendall, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the addition of fedratinib (Inrebic) to the treatment paradigm in myelofibrosis.

Fedratinib is a relatively old drug that went through extensive clinical trials and was tested in many patients several years ago. After going through phase III clinical trials in ruxolitinib (Jakafi) patients with myelofibrosis, fedratinib was put on hold.

Despite its setbacks, fedratinib experienced a resurgence where the safety signals were reexamined, and researchers took a closer look at its efficacy. Now, fedratinib is approved to treat patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis, giving patients the option of a second JAK inhibitor.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute